Topic Review
Atopic March or Atopic Multimorbidity
The atopic march encompasses a sequence of allergic conditions, including atopic dermatitis, food allergy, allergic rhinitis, and asthma, that frequently develop in a sequential pattern within the same individual. It was introduced as a conceptual framework aimed at elucidating the developmental trajectory of allergic conditions during childhood. Following the introduction of this concept, it was initially believed that the atopic march represented the sole and definitive trajectory of the development of allergic diseases. 
  • 169
  • 03 Jan 2024
Topic Review
Autophagy in Cisplatin Nephrotoxicity
Cisplatin is a potent chemotherapy drug used for the treatment of various types of tumors, but it has remarkable side effects or toxicity in normal tissues. The kidney is highly vulnerable to cisplatin toxicity due to the accumulation of cisplatin in renal tubule cells. Acute kidney injury occurs in 20–30% of patients and manifests as kidney cell death, tissue damage, rapid loss of renal function or renal failure, and even death.
  • 492
  • 24 Nov 2021
Topic Review
B Cells in Autoimmunity
B cells are key players in this relationship because activated and differentiated B cells produce secretory immunoglobulin A (sIgA), which binds commensal bacteria to preserve a healthy microbial ecosystem.
  • 427
  • 18 May 2021
Topic Review
Balance Remains Impaired after Hip Arthroplasty
Hip arthroplasty (HA) is the end-stage intervention for patients affected by hip osteoarthritis (OA). It is the most common joint replacement procedure and the number of patients undergoing prosthetic implantation is progressively growing due to the ageing population. The evidence suggested that balance is impaired immediately after surgery and, 4–12 months after surgery, it becomes better than preoperatively, although without reaching the level of healthy subjects. A strong level of evidence was found for hip resurfacing resulting in better balance restoration than total HA (THA), and for strength and ROM exercises after surgery positively influencing balance. 
  • 1.4K
  • 23 Mar 2022
Topic Review
Bioactivities of Turmeric Oil
Curcuma longa L. (syn. Curcuma domestica), commonly known as turmeric, is a perennial herb native to Asia. After curing, drying, and milling, turmeric rhizomes are usually employed as a dye, cosmetic, and food seasoning. Most pharmacological activities of turmeric have been explained by the properties of curcumin, mainly because turmeric oil has not been as extensively studied as curcuminoids. Turmeric rhizome oil (TO) is responsible for this spice’s characteristic taste and smell.
  • 445
  • 16 Aug 2022
Topic Review
BioFilms
Biofilms are aggregates formed as a protective survival state by microorganisms to adapt to the environment and can be resistant to antimicrobial agents and host immune responses due to chemical or physical diffusion barriers, modified nutrient environments, suppression of the growth rate within biofilms, and the genetic adaptation of cells within biofilms. With the widespread use of medical devices, medical device-associated biofilms continue to pose a serious threat to human health, and these biofilms have become the most important source of nosocomial infections. However, traditional antimicrobial agents cannot completely eliminate medical device-associated biofilms. New strategies for the treatment of these biofilms and targeting biofilm infections are urgently required. Several novel approaches have been developed and identified as effective and promising treatments.
  • 1.2K
  • 13 Apr 2021
Topic Review
Biological Drugs in EoE and Their Targets
Eosinophilic esophagitis (EoE) is a multifaceted disease characterized by a wide heterogeneity of clinical manifestations, endoscopic and histopathologic patterns, and responsiveness to therapy. From the perspective of an effective approach to the patient, the different inflammatory mechanisms involved in the pathogenesis of EoE and biologics, in particular monoclonal antibodies (mAbs), targeting these pathways are needed. Currently, the most relevant is dupilumab, which interferes with both interleukin (IL)-4 and IL-13 pathways by binding IL-4 receptor α, and is the only mAb approved by the European Medicine Agency and US Food and Drug Administration for the treatment of EoE. Other mAbs investigated include mepolizumab, reslizumab, and benralizumab (interfering with IL-5 axis), cendakimab and dectrekumab (anti-IL-13s), tezepelumab (anti-TSLP), lirentelimab (anti-SIGLEG-8), and many others.
  • 72
  • 08 Feb 2024
Topic Review
Biomarkers of Allergic Asthma
Allergic asthma is the most common asthma phenotype and is characterized by IgE sensitization to airborne allergens and subsequent typical asthmatic symptoms after exposure. A form of type 2 (T2) airway inflammation underlies allergic asthma. It usually arises in childhood and is accompanied by multimorbidity presenting with the occurrence of other atopic diseases, such as atopic dermatitis and allergic rhinitis. Biomarkers identifying patients with allergic asthma include total immunoglobulin E (IgE) levels, fractional exhaled nitric oxide (FeNO) and serum eosinophil counts. 
  • 577
  • 28 Jul 2022
Topic Review
Bradykinin Metabolism
Bradykinin (BK) metabolism and its receptors play a central role in drug-induced angioedema (AE) without urticaria through increased vascular permeability. Many cardiovascular and diabetic drugs may cause BK-mediated AE. Angiotensin-converting enzyme inhibitors (ACEIs) and neprilysin inhibitors impair BK catabolism.
  • 161
  • 26 Jul 2023
Topic Review
BRAF V600K-Mutant Cutaneous Melanoma
BRAF is a serine/threonine protein kinase that, activating MAPK and ERK signalling, is involved in cell proliferation. About 50% of melanomas harbour a BRAF mutation. Of these 50%, 10% have a V600K mutation. Recent findings have underlined how melanoma V600K seems to be less dependent on the ERK/MAPK pathway, with a higher expression of PI3KB and a strong inhibition of multiple antiapoptotic pathways. Both target therapy with BRAF inhibitors + MEK inhibitors and immunotherapy with anti-checkpoint blockades are effective in melanoma V600K, although no sufficient evidence can currently support a formal recommendation for first line treatment choice in IIIC unresectable/IV stage patients.
  • 594
  • 15 Feb 2022
  • Page
  • of
  • 36